SignalChem Lifesciences Corporation (SLC) - Similar companies

Headquartered in British Columbia, Canada, SignalChem was established in 2004 and became a global leader in cell signaling an ... d protein engineering. The company employs 60 scientists and consists of four business units. SignalChem’s Bioreagent unit generates worldwide, annual sales expected to reach ~$8M this year. This unit’s success has enabled the Drug Discovery unit to remain non-diluted and self-funded. The Drug Discovery unit includes five projects in various stages of development benefiting from the company’s core expertise and knowledge. SLC-391 (a potent and selective AXL inhibitor) is its most advanced program in late-Phase I clinical development. SignalChem is now entering its first-ever round of financing, seeking $20M to complete Phase II clinical development in oncology, which is planned to start in Q1, 2022. SignalChem is open to a variety of business/financial models to support our efforts to bring SLC-391 to patients suffering from Cancer. To learn more about SLC-391, join us for a partnering meeting or attend our conference presentation. We look forward to meeting you. read more